Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 434

1.

Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.

Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN.

Ann Oncol. 2013 Jul;24(7):1802-7. doi: 10.1093/annonc/mdt138. Epub 2013 Apr 12.

PMID:
23585511
2.

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C.

Ann Oncol. 2013 Jul;24(7):1807-12. doi: 10.1093/annonc/mdt136. Epub 2013 Apr 10.

PMID:
23576708
3.

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.

Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22.

4.

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.

Eur Urol. 2015 Aug;68(2):317-24. doi: 10.1016/j.eururo.2014.07.028. Epub 2014 Aug 6.

PMID:
25108579
5.

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.

Clin Genitourin Cancer. 2015 Aug;13(4):392-9. doi: 10.1016/j.clgc.2015.01.004. Epub 2015 Jan 24.

PMID:
25708161
6.

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.

Eur Urol. 2015 Jan;67(1):23-9. doi: 10.1016/j.eururo.2014.06.045. Epub 2014 Jul 10.

PMID:
25018038
7.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
8.

Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.

Eur Urol. 2014 Jan;65(1):30-6. doi: 10.1016/j.eururo.2013.06.042. Epub 2013 Jul 2.

PMID:
23849416
9.

Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.

Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.

Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189. Epub 2013 Nov 21.

PMID:
24255983
10.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

11.

[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].

Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szûcs M, Berczi C, Gulácsi L.

Magy Onkol. 2014 Sep;58(3):189-97. Epub 2014 Aug 2. Review. Hungarian.

12.

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20.

13.

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.

Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30.

14.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

15.

Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.

Davies RS, Smith C, Lester JF.

Anticancer Res. 2016 Apr;36(4):1799-803.

PMID:
27069162
16.

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.

BMC Res Notes. 2016 Oct 18;9(1):471.

17.

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.

Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.

Eur J Cancer. 2014 Jan;50(1):78-84. doi: 10.1016/j.ejca.2013.08.020. Epub 2013 Sep 25.

PMID:
24074764
18.

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.

Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.

PMID:
25175831
19.

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.

Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044. Epub 2013 Dec 17.

PMID:
24411987
20.

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N, Clayton R, Heng DY, Joshua AM, Chi KN.

Eur Urol. 2015 Mar;67(3):441-7. doi: 10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31.

PMID:
24508071

Supplemental Content

Support Center